Search
01/05/2025
Impact of physical exercise and protein-enriched nutritional support on the development of post-TIPS hepatic encephalopathy
Baiges, A, Téllez, L, Darnell, A, Borda, D, Alvarado-Tapias, E, Soriano, G, Ferrusquía-Acosta, J, Oña, L, Donate, J, Olavarría, A, Gomez, A, Trabal, J, Costas, A, Sanchez, MM, Lazcano, AL, León, L, Perez, V, Casals, C, Hervas, A, Orts, L, Laxe, S, Closa, C, García-Calderó, H, Madubashetha, H, Turon, F, Hernández-Gea, V, Albillos, A, Garcia-Pagan, JC. Impact of physical exercise and protein-enriched nutritional support on the development of post-TIPS hepatic encephalopathy. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Variables associated with postoperative mortality in advanced chronic liver disease patients undergoing urgent or elective surgery. a multicentre spanish cohort
Canillas, L, Jimenez-Esquivel, N, Amador, A, Brujats, A, Sánchez, J, Pelegrina, A, Pardo, C, Montaña, SH, Camps, M, de Sárraga, C, Vizoso, A, Alvarez, J, Burdio, F, Reverter, E, Carrión, JA. Variables associated with postoperative mortality in advanced chronic liver disease patients undergoing urgent or elective surgery. a multicentre spanish cohort. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice
Olveira, A, Crespo, J, Samaniego, LI, Gallego-Durán, R, Panero, JLC, Aller, R, Soria, A, Gómez-Camarero, J, Martin-Mateos, R, Benlloch, S, Pericàs, JM, Morillas, RM, Bernal, V, Diago, M, Turnes, J, Poca, M, Lo Iacono, O, Escudero-García, D, Andrade, RJ, Rosales-Zábal, JM, Jorquera, F, Fernández-Rodríguez, C, Guerra, MH, Romero-Gómez, M, Herrojo, JA. Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study
Guerrero, A, Verdyguer, MR, Martínez, SM, Campos, M, Sogbe, M, Fajes, JLH, Pascual, S, Cuyas, B, Minguez, B, Lamas-Alvarez, S, Fortea, J, Lopez-Fando, MPV, Lozano, MD, Gómez-Rubio, M, Perelló, C, Gutiérrez, ML, Romero-Gutiérrez, M, Mancebo, A, Planas, JMM, Téllez, L, Panero, JLC, De la Poza, G, Piqueras, B, Puente, A, Varela, M, Genesca, J, Alvarado-Tapias, E, D'Avola, D, Matilla, A, Sangro, B, Reig, M, Lledó, JL, Albillos, A. Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study
Alabau, BB, Plessier, A, Sanchez, FB, Payancé, A, Ballester, TG, Elkrief, L, Sánchez-Lorenzo, A, Larrue, H, Donate, J, Vidal-González, J, Praktiknjo, M, González-Alayón, C, Tripathi, D, Fortea, J, Gioia, S, alvarez-Navascués, C, Raevens, S, Herrera, EL, Protopapas, A, Nery, FGC, Artaza, T, La Mura, V, Baiges, A, Ollivier-Hourmand, I, Darnell, A, Zekrini, K, Belmonte, E, García-Criado, MA, Turon, F, Hernández-Gea, V, Verhelst, X, Riggio, O, Puente, A, Simon-Talero, M, Téllez, L, Bureau, C, Alvarado-Tapias, E, Ballester, MP, Rautou, PE, García-Pagán, JC. Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).
01/05/2025
Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort
Younossi, Z, de Avila, L, Petta, S, Nakajima, A, Crespo, J, Kim, SU, Castera, L, Zheng, MH, Tsochatzis, E, Trivikrama, SK, Shalimar, S, Alswat, KA, Yilmaz, Y, Yu, ML, Francque, S, Chan, WK, Fernández, MIC, Treeprasertsuk, S, Duseja, AK, Gadano, A, Oliveira, CP, Arab, JP, Papatheodoridis, G, Diaz, LA, Sebastiani, G, D'Ambrosio, R, Valsan, A, Khalid, A, Holleboom, AG, El-Kassas, M, Pugliese, N, Singal, AK, Pearlman, B, Choudhary, NS, Cordie, A, Gunn, N, Caussy, C, Mauricio, D, Kawaguchi, T, Russo, FP, Venu, A, Hagström, H, Alkhouri, N, Ananchuensook, P, Mohan, L, Fan, JA, Roberts, S, Wong, VWS, Dunn, W, Ekstedt, M, Goh, GBB, Pessoa, M, Lampertico, P, Pennisi, G, Shang, Y, Liu, WY, Lee, HW, Kobayashi, T, Kakizaki, S, Iruzubieta, P, Nadeem, R, Cinque, F, Neonaki, A, Zoncapè, M, Yang, RX, Song, SJ, Dunn, N, Gadi, Z, Yeh, ML, Teh, KKJ, Mahadeva, S, Fabian, LG, Almohsen, A, Leite, N, Vessby, J, Xie, CC, Friend, E, Poca, M, Segrestin, B, Arrese, M, Lam, B, Racila, A, Alqahtani, S, Stepanova, M. Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort. JOURNAL OF HEPATOLOGY. 2025; 82DOI:. PMID:. IF:33.000(Q1/1D).